Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Tobramycin | Tofibra | 4.4 Special Warnings and Special Precautions for Use | Increased risk of aminoglycoside-associated ototoxicity in patients with mitochondrial mutations | Sep,2023 |
| Amikacin | Miacin | 4.4 Special Warnings and Special Precautions for Use | Increased risk of aminoglycoside-associated ototoxicity in patients with mitochondrial mutations | Sep,2023 |
| Macitentan | Opsumit | 4.8 Undesirable effects | Risk of flushing | May,2023 |
| Atezolizumab | Tecentriq | 4.8 Undesirable effects | Pericarditis, pericardial effusion, cardiac tamponade | May,2023 |
| Selpercatinib | Retsevmo | 4.4 Special Warnings and Special Precautions for Use, 4.8 Undesirable effects | Interstitial Lung Disease /Pneumonitis | May,2023 |
| Meloxicam | Mobic | 4.4 Special Warnings and Special Precautions for Use | Fixed drug eruption | May,2023 |